Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CTSL | P07711 | 8/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842668 | 0.93 | CTSS (0.55) | CTSSCTSKCTSLPTPN1GAA | |
| SCHEMBL5842773 | 0.87 | CTSS (0.47) | CTSSCTSKCTSLALDH1A1 | |
| SCHEMBL5843012 | 0.85 | CTSS (0.48) | CTSSCTSKCTSL | |
| SCHEMBL5842546 | 0.84 | CTSL (0.67) | CTSSCTSKCTSL | |
| SCHEMBL5842674 | 0.83 | CTSS (0.48) | CTSSCTSKCTSLPTPN1 | |
| SCHEMBL5842009 | 0.83 | CTSS (0.57) | CTSSCTSKCTSLALDH1A1 | |
| SCHEMBL5843392 | 0.83 | CTSS (0.60) | CTSSCTSKCTSLRAB9AALDH1A1 | |
| SCHEMBL5844635 | 0.83 | CTSS (0.54) | CTSSCTSKCTSL | |
| SCHEMBL5843947 | 0.82 | CTSS (0.66) | CTSSCTSKCTSLALDH1A1 | |
| SCHEMBL5844379 | 0.82 | CTSS (0.57) | CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | CTSS 1/4885CTSK 2/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.